BMO Capital Maintains Outperform on Novo Nordisk, Lowers Price Target to $156

Benzinga · 10/17 13:57
BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Outperform and lowers the price target from $160 to $156.